FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where...
Autors principals: | Wong, K, Gascoyne, D, Soilleux, E, Lyne, L, Spearman, H, Banham, A, Roncador, G, Pedersen, L, Moller, M, Green, T |
---|---|
Format: | Journal article |
Publicat: |
Impact Journals
2016
|
Ítems similars
-
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
per: Brown, P, et al.
Publicat: (2015) -
Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients
per: Wong, K, et al.
Publicat: (2014) -
Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
per: Wong, K, et al.
Publicat: (2014) -
The significance of FOXP1 in diffuse large B-cell lymphoma
per: Gascoyne, D, et al.
Publicat: (2016) -
Vitamin D receptor expression in plasmablastic lymphoma and myeloma cells confers susceptibility to vitamin D
per: Gascoyne, D, et al.
Publicat: (2016)